



DAILY PROGRAMME HIGHLIGHTS

4th IAS Conference on HIV Pathogenesis,
Treatment and Prevention
Sydney, Australia – 22-25 July 2007

Please visit the online [Programme-at-a-Glance](http://www.ias2007.org) (www.ias2007.org) for a full list of conference sessions and satellite meetings taking place at the Sydney Convention and Exhibition Centre.

Third-party press conferences: please note that a number of organizations will hold press conferences during the conference. A schedule of all third-party press conferences taking place in the Media Centre is included in the press kit and posted to the Media Centre page of the conference website. Daily schedules will also be posted at the Information Booth in the Media Centre. **Please check on-site for the most up-to-date information on all press conferences.**

SUNDAY, 22 JULY

08:00 – 10:00

Satellite Session

Are We Prepared for PrEP? The Challenges of Implementing Proven Biomedical Prevention Technologies

Sponsors: IAS Industry Liaison Forum (ILF)

Location: Parkside Ballroom B

A multi-stakeholder discussion of challenges and potential strategies for implementing Pre-exposure Prophylaxis (PrEP) as a promising new HIV prevention tool.

12:30 – 14:30

Satellites Session

HIV/TB Co-Infection: Meeting the Challenge

Sponsors: World Health Organization's (WHO) HIV-TB Working Group, IAS, EDCTP, National Institutes of Health (NIH), BMGF, Tibotec, CREATE and the Forum for Collaborative Research

Location: Parkside Ballroom

An overview of the current status of research on HIV-TB diagnosis and treatment strategies, including multi-drug resistant (MDR) and extremely drug resistant (XDR) TB, and HIV-TB co-infection in children, followed by a panel discussion with major sponsors and program representatives.

14:45 – 16:45

Satellite Session

Access to Care in the Context of HIV Vaccine and Other Prevention Trials: Setting Standards and Making it Happen Through Participation

Sponsors: WHO, Joint United Nations Programme on HIV/AIDS (UNAIDS), and the University of New South Wales

Location: Parkside Ballroom B

This satellite will present a range of perspectives on what an appropriate standard of care should be for vaccine and other prevention trial participants, and will include discussion of a proposal for the use of a participatory process to establish such standards.

16:00 – 17:00

Official Opening Press Conference

Hosts: 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention

Location: Press Conference Room, Media Centre (Parkside 110)

This press conference will feature the opening session speakers, and gives journalists the opportunity to gain a summarized preview of opening session topics, and ask questions of the speakers:

- Dr. Pedro Cahn, IAS President and Conference Co-Chair
- Dr. David Cooper, Local Conference Co-Chair and Director, National Centre in HIV Epidemiology and Clinical Research, University of New South Wales
- Dr. Anthony Fauci, Director, National Institute of Allergy and Infectious Diseases/NIH
- Dr. Michel Kazatchkine, Executive Director, Global Fund for AIDS, Tuberculosis and Malaria

17:00 – 19:00

Satellite Session

"Doing it Down Under" – Critical reflections on Australia's HIV response

Sponsors: New South Wales Health and National Centre in HIV Social Research, University of NSW, Sydney

Location: Parkside Ballroom B

A panel of Australian experts will explore how Sydney has bucked national and international trends with its observed downturn in sexual risk behavior and a slowing of HIV transmission among men who have sex with men (MSM).

19:30 – 21:30

Opening Session

Location: Bayside Auditorium

Welcome remarks by the IAS 2007 Conference Co-Chairs; Robert Welsh, Chairperson of the Metropolitan Local Aboriginal Land Council; Hon. Tony Abbot, Australian Minister for Health and Ageing; and a representative from the government of New South Wales (TBC). The session will also include an introduction of the Sydney Declaration -- a global sign-on letter calling for an increase in HIV research -- and keynote addresses by:

- Professor Michel Kazatchkine, Executive Director, Global Fund for AIDS, Tuberculosis and Malaria;
- Dr. Anthony Fauci, Director, National Institute of Allergy and Infectious Diseases/NIH; and
- Maura Elaripe Mea, Community Representative, Papua New Guinea.

The Opening Session will also include dance performances by the Sydney-based Aboriginal ensemble, Descendance Cultural Group.

MONDAY, 23 JULY

9:00 – 10:30

Plenary

The HIV/Life Cycle: Understanding HIV Pathogenesis, Accelerating ARV Rollout and Exploring the Clinical Implications of Ageing

Location: Bayside Auditorium B

- Dr. Debrework Zewdie, World Bank, *Understanding the task: ARV rollout and research issues in the developing world*
- Dr. Michael Lederman, Case Western Reserve University, *How HIV makes you sick: mechanisms of CD4 T cell loss and recovery*
- Dr. Brian Gazzard, Chelsea Westminster Hospital, *Ageing and AIDS: new clinical endpoints in HIV practice*

11:00 – 12:00

OFFICIAL PRESS CONFERENCE MEET THE PLENARY SPEAKERS

Location: Media Centre, Press Conference Room

11:00 – 12:30

Oral Abstract Session

TB/HIV: Still a Deadly Partnership

Location: Bayside Auditorium B

Worldwide, TB is the most common presenting illness among people receiving ART and a leading killer of people with HIV.

Oral Abstract Session

Global Responses to HIV Prevention Among Injection Drug Users

Location: Parkside Auditorium

This session will feature recent research among injecting drug users in both developed and developing countries.

13:00 – 14:00

SPECIAL SESSION

New Data and International Antiretroviral Treatment

Guidelines: Interactive, State-of-the-Art Session

Location: Bayside Auditorium B

This interactive session will focus on new data in the key areas of antiretroviral therapy and discuss how these data will impact developed-world guidelines, including the IAS-USA guidelines and Australian national guidelines, as well as developing-world guidelines. Issues to be discussed include when to start therapy and with what drugs, when to change therapy and to what, and the impact new data on the WHO guidelines for treatment in resource-limited areas of the world.

14:30 – 16:00

Bridging Session

Hepatitis Co-Infection: Not as easy as A, B, C

Location: Bayside Auditorium B

A multidisciplinary, cross-track look at HIV/Hepatitis co-infection.

Oral Abstract Session

Ethics in Biomedical Prevention

Location: Parkside Auditorium B

Informed consent and access to care and treatment for prevention trial participants are among the topics to be discussed in this oral abstract session.

16:30 – 18:00

Symposium

Treatment of Early HIV Disease

Location: Bayside Auditorium

Emerging questions regarding the effectiveness and feasibility of treating early HIV disease will be the focus of this symposium chaired the NIAID Director Dr. Anthony Fauci.

Bridging Session

Prophylactic HIV Vaccines: Where are we?

Location: Parkside Ballroom B

With more than two dozen clinical trials of HIV vaccine candidates currently in progress, this bridging session will feature presentations and discussion of where we stand on several key research questions.

Symposium

Emerging Challenges in Designing Prevention Research

Location: Parkside Auditorium

Issues related to trial design and other challenges will be discussed by speakers and delegates in this symposium that will explore what must be done to move prevention research forward.

TUESDAY, 24 JULY

9:00 – 10:30

Plenary

Promising Research and the Road to Practice: The Prospects for RNA Interference, Next Steps on Male Circumcision and Novel Treatments on the Horizon

Location: Bayside Auditorium B

- Dr. Robert Bailey, University of Illinois at Chicago, *Scaling up circumcision programmes: the road from evidence to practice*
- Dr. John Rossi, City of Hope Beckman Research Institute, *Interference and inhibition: RNAi mechanisms and therapeutic prospects*
- Dr. Joseph Eron, University of North Carolina Chapel Hill, *New kids on the block: novel agents and treatment strategies*

11:00 – 12:00

OFFICIAL PRESS CONFERENCE MEET THE PLENARY SPEAKERS

Location: Media Centre, Press Conference Room

11:00 – 12:30

Oral Abstract Session

Clinical Trials of ART

Location: Bayside Auditorium

This abstract session will focus on one of the most important developments in HIV over the past year, the emergence of exciting new treatment options.

Oral Abstract Session

Female Initiated HIV Prevention Technology

Location: Bayside Auditorium A

This session will feature abstract presentations on a number of exciting tools currently being researched, including the use of gels and cervical barriers, such as the diaphragm.

13:00 – 14:00

SPECIAL SESSION

The Future of Global Financing of HIV Prevention, Treatment, Care and Research

Location: Bayside Auditorium B

This panel will feature brief remarks and a panel discussion with newly appointed Global Fund Executive Director Dr. Michel Kazatchkine, Dr. Judy Auerbach, Director for Science and Public

Policy at the SF AIDS Foundation, and Dr. Debrework Zwedie, Director of the World Bank's Global HIV/AIDS Program. The session will be Co-Chaired by IAS President Dr. Pedro Cahn and Australian AIDS Ambassador Annmaree O'Keefe.

14:30 – 16:00

Oral Abstract Session

Prevention of Mother-to-Child Transmission

Location: Parkside Auditorium

This session will feature abstract presentations related to the effectiveness of antiretroviral therapy, breastfeeding and maternal and fetal safety.

Symposium

HIV Testing: Increasing Access, Increasing Uptake, and Protecting Human Rights

Location: Bayside Auditorium A

This session will feature a presentation on WHO's new HIV testing guidelines by Dr. Kevin de Cock (WHO's Director of HIV/AIDS), followed by presentations on related human rights issues and the experience with testing in Botswana and the U.S.

16:30 – 18:00

Oral Abstract Session

Paediatric HIV Infection: What's New?

Location: Parkside Auditorium

Paediatric HIV transmission, diagnosis and management will be the focus of abstract presentations in this session.

Oral Abstract Session

The Intersection of Biomedical and Social Aspects of Prevention

Location: Bayside Auditorium B

This session will explore some of the social aspects of HIV prevention that often lead to controversies in prevention research and the implementation of proven strategies.

Symposium

HIV/TB: An Evolving Epidemic

Location: Bayside Auditorium B

This session will review global efforts and feature presentations on recent clinical research related to TB and HIV co-infection.

WEDNESDAY, 25 JULY

9:00 – 10:30

Plenary

Getting Ahead of the Curve: Current Issues in Paediatric Treatment, Virology and Biomedical Prevention Science

Location: Bayside Auditorium B

- Dr. Annette Sohn, University of California, San Francisco, *Keeping up with the kids: Paediatric treatment issues*
- Dr. Ben Burkhout, University of Amsterdam, *Outpacing HIV: viral fitness, escape routes and resistance patterns*
- Dr. Nancy Padian, University of California, San Francisco's Women's Global Health Imperative, *Synthesizing our options: biomedical prevention technologies in the context of behavioural interventions*

11:00 – 12:00

OFFICIAL PRESS CONFERENCE

MEET THE PLENARY SPEAKERS

Location: Media Centre, Press Conference Room

11:00 – 12:30

Oral Abstract Session

Antiretroviral Treatment Failure in Resource Limited Settings

Location: Bayside Auditorium B

While the world struggles to provide even first-line HIV therapies to most of the developing world, researchers are also monitoring the emergence of resistance and examples of treatment failure.

Oral Abstract Session

Male Circumcision: The Cutting Edge of HIV Prevention

Location: Parkside Auditorium A

On the heels of research showing the tremendous effectiveness of male circumcision as an HIV prevention tool, panelists will explore various implementation issues on the horizon.

13:00 – 14:00

SPECIAL SESSION:

Late Breaker Oral Abstract Session TRACK B (1 of 2)

Location: Bayside Auditorium B

Due to the large volume of late breaker abstracts submitted in Track B, organizers have scheduled a second Track B Late

Breaker session at 16:30. Both sessions will feature presentations on exciting developments in clinical research, treatment and care, including the emergence of novel treatments that would offer new hope to those with resistant HIV.

14:30 – 16:00

Bridging Session

Microbicides and Mucosal Immunity

Location: Bayside Auditorium B

Presentations will explore new strategies, possible products, and the role of mucosal immunity and will provide an update on ongoing Phase III trials of microbicides.

16:30 – 17:30

SPECIAL SESSIONS:

Late Breaker Oral Abstract Session TRACK B (2 of 2)

Location: Bayside Auditorium B

Late Breaker Oral Abstract Session TRACKS A & C

Location: Bayside Auditorium A

17:30 – 18:45

Rapporteur Summaries and Closing Session

Location: Bayside Auditorium B

The Rapporteur Session will include oral reports summarizing the major findings and issues discussed in each of the three conference tracks, as well as a community statement.

Rapporteur Summaries will be followed by summary remarks by the Conference Co-Chairs, Drs. Cooper and Cahn, including a formal presentation of the Sydney Declaration, which calls for the scale up of HIV research as an essential part of a comprehensive response to HIV.

The Closing Session will conclude with brief introductory remarks from IAS 2009 Local Co-Chair Dr. Hoosen Coovadia, representing Cape Town, South Africa.